MicrobiAr: Characterization and Follow-up of Microbiome and Health Indicators in Obese, Pre-Diabetes and Type 2 Diabetes Cohorts Undergoing a Plant-based Diet and Lifestyle Intervention
The incidence of type 2 diabetes worldwide is growing rapidly, being one of the fastest growing global health emergencies of the 21st century according to the International Diabetes Federation. In MicrobiAr the investigators seek to achieve type 2 diabetes remission through a plant-based diet and lifestyle intervention identifying and characterizing key changes on the gut microbiome during clinical transitions. Specifically, the investigators aim to characterize and follow-up metabolic pathways from gut microbiome and how they evolve as long as health indicators do over the 2 years of this study.
• Subjects without type 2 diabetes, obesity, prediabetes (glucose intolerance), or metabolic syndrome
• HbA1c less than 42mmol/mol (\<5.7%)
• BMI between 18.5 and 24.9
• BMI greater than 30
• Fasting glucose between 110 and 125 mg/dl
• HbA1c between 42 and 47 mmol/mol (5.7% to 6.4%)
• BMI greater than 30
• Fasting glucose \> 126 mg/dl
• HbA1c \> 48mmol/mol (6.5% or higher)
• BMI greater than 30
• Treatment with metformin at therapeutic dose (1500-2000 mg/day) or maximum tolerated dose.